{"id":"NCT00479401","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients","officialTitle":"A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2008-11","completion":null,"firstPosted":"2007-05-28","resultsPosted":"2010-04-15","lastUpdate":"2014-07-17"},"enrollment":539,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Early Parkinson Disease (Early PD)"],"interventions":[{"type":"DRUG","name":"Pramipexol Extended Release","otherNames":[]},{"type":"DRUG","name":"Pramipexol Immediate Release","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pramipexole Extended Release (PPX ER)","type":"EXPERIMENTAL"},{"label":"Pramipexole Immediate Release (PPX IR)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II and III combined), safety, and tolerability of Pramipexole Extended Release (ER) (in daily doses from 0.375mg to 4.5mg q.d.) in comparison to placebo, and to test for non-inferiority between the two formulations (ER and IR) of pramipexole.\n\nIn addition, the efficacy of Pramipexole Immediate Release (IR) will be compared to placebo, for assay sensitivity","primaryOutcome":{"measure":"Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score","timeFrame":"baseline and after 33 weeks treatment","effectByArm":[{"arm":"Pramipexole Extended Release (PPX ER)","deltaMin":-8.6,"sd":null},{"arm":"Pramipexole Immediate Release (PPX IR)","deltaMin":-8.8,"sd":null},{"arm":"Placebo","deltaMin":-3.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":95,"countries":["United States","Argentina","Austria","Czechia","Finland","Germany","Hungary","India","Japan","Malaysia","Russia","Slovakia","Taiwan","Ukraine"]},"refs":{"pmids":[],"seeAlso":["http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.524_Literature.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":223},"commonTop":["Somnolence","Nausea","Constipation","Dizziness","Oedema peripheral"]}}